Neurocrine Biosciences Profit Margin

The latest profit margin for NBIX is 20.91% as of June 2026. That compares with 13.88% in the prior-year period — up 50.7% year over year. That is above the Healthcare sector average of 13.76%. Investors often review this figure alongside Neurocrine Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, NBIX's profit margin moved from 13.88% to 20.91% — a 50.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neurocrine Biosciences's valuation or profitability profile.

Against Healthcare companies, NBIX currently prints 20.91% for profit margin, while the sector average sits near 13.76%. That is roughly 52.0% above the sector mean. Large gaps often invite a closer look at Neurocrine Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Neurocrine Biosciences converts resources into returns. At 20.91%, NBIX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 13.88% in the prior-year period — up 50.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NBIX's profit margin (20.91%), review year-over-year change from 13.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.